Titre : Benzazépines

Benzazépines : Questions médicales fréquentes

Nom anglais: Benzazepines

Descriptor UI: D001552

Tree Number: D03.633.100.079

Termes MeSH sélectionnés :

Movement Disorders

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzazépines ?

Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont liés aux benzazépines ?

Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines.
Trouble d'usage de substances Benzodiazépines
#4

Comment évaluer les effets secondaires des benzazépines ?

L'évaluation se fait par l'observation des symptômes et l'historique médical du patient.
Effets secondaires Benzodiazépines
#5

Quels signes indiquent une surdose de benzazépines ?

Les signes incluent confusion, somnolence excessive, et dépression respiratoire.
Surdose Benzodiazépines

Symptômes 5

#1

Quels sont les symptômes d'une surconsommation de benzazépines ?

Les symptômes incluent somnolence, confusion, et troubles de la coordination.
Symptômes Benzodiazépines
#2

Comment se manifeste le sevrage des benzazépines ?

Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions.
Sevrage Benzodiazépines
#3

Quels effets à long terme des benzazépines ?

Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance.
Effets à long terme Benzodiazépines
#4

Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?

Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil.
Anxiété Benzodiazépines
#5

Les benzazépines causent-elles des troubles de la mémoire ?

Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose.
Troubles de la mémoire Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzazépines ?

Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives.
Prévention Dépendance aux médicaments
#2

Quelles sont les recommandations pour l'utilisation des benzazépines ?

Utiliser à la dose minimale efficace et pour la durée la plus courte possible.
Recommandations Benzodiazépines
#3

Comment éduquer les patients sur les benzazépines ?

Informer sur les risques, les effets secondaires et l'importance du suivi médical.
Éducation des patients Benzodiazépines
#4

Quels sont les risques d'auto-médication avec des benzazépines ?

L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses.
Auto-médication Benzodiazépines
#5

Comment réduire l'usage des benzazépines dans la population ?

Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés.
Réduction de l'usage Benzodiazépines

Traitements 5

#1

Comment sont prescrites les benzazépines ?

Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines.
Prescription Benzodiazépines
#2

Quelles alternatives aux benzazépines pour l'anxiété ?

Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives.
Antidépresseurs Anxiété
#3

Comment gérer une overdose de benzazépines ?

L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil.
Overdose Benzodiazépines
#4

Les benzazépines sont-elles efficaces pour l'insomnie ?

Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires.
Insomnie Benzodiazépines
#5

Quel suivi est nécessaire lors de l'utilisation de benzazépines ?

Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires.
Suivi médical Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec les benzazépines ?

Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence.
Complications Benzodiazépines
#2

Les benzazépines augmentent-elles le risque de chutes ?

Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées.
Chutes Benzodiazépines
#3

Comment les benzazépines affectent-elles la respiration ?

Elles peuvent déprimer le système respiratoire, surtout en cas de surdose.
Dépression respiratoire Benzodiazépines
#4

Les benzazépines peuvent-elles interagir avec d'autres médicaments ?

Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs.
Interactions médicamenteuses Benzodiazépines
#5

Quels sont les effets des benzazépines sur la grossesse ?

Elles peuvent causer des malformations congénitales et des complications néonatales.
Grossesse Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance aux benzazépines ?

Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque.
Dépendance Benzodiazépines
#2

Les personnes âgées sont-elles plus à risque avec les benzazépines ?

Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes.
Personnes âgées Benzodiazépines
#3

Comment l'usage prolongé de benzazépines affecte-t-il le risque ?

L'usage prolongé augmente le risque de dépendance et de troubles cognitifs.
Usage prolongé Benzodiazépines
#4

Quels facteurs psychologiques influencent l'usage des benzazépines ?

L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines.
Facteurs psychologiques Benzodiazépines
#5

Les interactions médicamenteuses augmentent-elles les risques ?

Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents.
Interactions médicamenteuses Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzazépines : Questions médicales les plus fréquentes", "headline": "Benzazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "url": "https://questionsmedicales.fr/mesh/D001569", "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Diltiazem", "alternateName": "Diltiazem", "url": "https://questionsmedicales.fr/mesh/D004110", "about": { "@type": "MedicalCondition", "name": "Diltiazem", "code": { "@type": "MedicalCode", "code": "D004110", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.150" } } }, { "@type": "MedicalWebPage", "name": "Fénoldopam", "alternateName": "Fenoldopam", "url": "https://questionsmedicales.fr/mesh/D018818", "about": { "@type": "MedicalCondition", "name": "Fénoldopam", "code": { "@type": "MedicalCode", "code": "D018818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.300" } } }, { "@type": "MedicalWebPage", "name": "Galantamine", "alternateName": "Galantamine", "url": "https://questionsmedicales.fr/mesh/D005702", "about": { "@type": "MedicalCondition", "name": "Galantamine", "code": { "@type": "MedicalCode", "code": "D005702", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.525" } } }, { "@type": "MedicalWebPage", "name": "Ivabradine", "alternateName": "Ivabradine", "url": "https://questionsmedicales.fr/mesh/D000077550", "about": { "@type": "MedicalCondition", "name": "Ivabradine", "code": { "@type": "MedicalCode", "code": "D000077550", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.801" } } }, { "@type": "MedicalWebPage", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "alternateName": "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine", "url": "https://questionsmedicales.fr/mesh/D015647", "about": { "@type": "MedicalCondition", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "code": { "@type": "MedicalCode", "code": "D015647", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.838" } } }, { "@type": "MedicalWebPage", "name": "Tolvaptan", "alternateName": "Tolvaptan", "url": "https://questionsmedicales.fr/mesh/D000077602", "about": { "@type": "MedicalCondition", "name": "Tolvaptan", "code": { "@type": "MedicalCode", "code": "D000077602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzazépines", "alternateName": "Benzazepines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Bernhard Wünsch", "url": "https://questionsmedicales.fr/author/Bernhard%20W%C3%BCnsch", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany." } }, { "@type": "Person", "name": "Dirk Schepmann", "url": "https://questionsmedicales.fr/author/Dirk%20Schepmann", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany." } }, { "@type": "Person", "name": "Simon M Ametamey", "url": "https://questionsmedicales.fr/author/Simon%20M%20Ametamey", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch." } }, { "@type": "Person", "name": "Nadine Ritter", "url": "https://questionsmedicales.fr/author/Nadine%20Ritter", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de." } }, { "@type": "Person", "name": "Guiscard Seebohm", "url": "https://questionsmedicales.fr/author/Guiscard%20Seebohm", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Neuropsychology and Movement Disorders.", "datePublished": "2024-06-17", "url": "https://questionsmedicales.fr/article/39343477", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ncl.2024.05.008" } }, { "@type": "ScholarlyArticle", "name": "Cannabinoids in movement disorders.", "datePublished": "2022-08-24", "url": "https://questionsmedicales.fr/article/36038457", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.parkreldis.2022.08.014" } }, { "@type": "ScholarlyArticle", "name": "Moving Beyond Movement: Diagnosing Functional Movement Disorder.", "datePublished": "2023-03-09", "url": "https://questionsmedicales.fr/article/36893796", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0043-1763505" } }, { "@type": "ScholarlyArticle", "name": "Impaired Metacognition of Voluntary Movement in Functional Movement Disorder.", "datePublished": "2023-01-06", "url": "https://questionsmedicales.fr/article/36606550", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mds.29303" } }, { "@type": "ScholarlyArticle", "name": "Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease.", "datePublished": "2022-07-05", "url": "https://questionsmedicales.fr/article/35787539", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/WCO.0000000000001075" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzazépines", "description": "Comment diagnostiquer une dépendance aux benzazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzazépines ?\nQuels critères DSM sont liés aux benzazépines ?\nComment évaluer les effets secondaires des benzazépines ?\nQuels signes indiquent une surdose de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Movement+Disorders#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzazépines", "description": "Quels sont les symptômes d'une surconsommation de benzazépines ?\nComment se manifeste le sevrage des benzazépines ?\nQuels effets à long terme des benzazépines ?\nQuels symptômes d'anxiété peuvent être soulagés par les benzazépines ?\nLes benzazépines causent-elles des troubles de la mémoire ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Movement+Disorders#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzazépines", "description": "Comment prévenir la dépendance aux benzazépines ?\nQuelles sont les recommandations pour l'utilisation des benzazépines ?\nComment éduquer les patients sur les benzazépines ?\nQuels sont les risques d'auto-médication avec des benzazépines ?\nComment réduire l'usage des benzazépines dans la population ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Movement+Disorders#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzazépines", "description": "Comment sont prescrites les benzazépines ?\nQuelles alternatives aux benzazépines pour l'anxiété ?\nComment gérer une overdose de benzazépines ?\nLes benzazépines sont-elles efficaces pour l'insomnie ?\nQuel suivi est nécessaire lors de l'utilisation de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Movement+Disorders#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzazépines", "description": "Quelles complications peuvent survenir avec les benzazépines ?\nLes benzazépines augmentent-elles le risque de chutes ?\nComment les benzazépines affectent-elles la respiration ?\nLes benzazépines peuvent-elles interagir avec d'autres médicaments ?\nQuels sont les effets des benzazépines sur la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Movement+Disorders#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzazépines", "description": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?\nLes personnes âgées sont-elles plus à risque avec les benzazépines ?\nComment l'usage prolongé de benzazépines affecte-t-il le risque ?\nQuels facteurs psychologiques influencent l'usage des benzazépines ?\nLes interactions médicamenteuses augmentent-elles les risques ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Movement+Disorders#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont liés aux benzazépines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des benzazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par l'observation des symptômes et l'historique médical du patient." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive, et dépression respiratoire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une surconsommation de benzazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent somnolence, confusion, et troubles de la coordination." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage des benzazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions." } }, { "@type": "Question", "name": "Quels effets à long terme des benzazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance." } }, { "@type": "Question", "name": "Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil." } }, { "@type": "Question", "name": "Les benzazépines causent-elles des troubles de la mémoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour l'utilisation des benzazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser à la dose minimale efficace et pour la durée la plus courte possible." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les benzazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Informer sur les risques, les effets secondaires et l'importance du suivi médical." } }, { "@type": "Question", "name": "Quels sont les risques d'auto-médication avec des benzazépines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses." } }, { "@type": "Question", "name": "Comment réduire l'usage des benzazépines dans la population ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés." } }, { "@type": "Question", "name": "Comment sont prescrites les benzazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles alternatives aux benzazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives." } }, { "@type": "Question", "name": "Comment gérer une overdose de benzazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil." } }, { "@type": "Question", "name": "Les benzazépines sont-elles efficaces pour l'insomnie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires." } }, { "@type": "Question", "name": "Quel suivi est nécessaire lors de l'utilisation de benzazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les benzazépines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence." } }, { "@type": "Question", "name": "Les benzazépines augmentent-elles le risque de chutes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Comment les benzazépines affectent-elles la respiration ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent déprimer le système respiratoire, surtout en cas de surdose." } }, { "@type": "Question", "name": "Les benzazépines peuvent-elles interagir avec d'autres médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs." } }, { "@type": "Question", "name": "Quels sont les effets des benzazépines sur la grossesse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent causer des malformations congénitales et des complications néonatales." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque avec les benzazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes." } }, { "@type": "Question", "name": "Comment l'usage prolongé de benzazépines affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé augmente le risque de dépendance et de troubles cognitifs." } }, { "@type": "Question", "name": "Quels facteurs psychologiques influencent l'usage des benzazépines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines." } }, { "@type": "Question", "name": "Les interactions médicamenteuses augmentent-elles les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 09/05/2025

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Sous-catégories

31 au total
└─

Benzodiazépines

Benzodiazepines D001569 - D03.633.100.079.080
└─

Diltiazem

Diltiazem D004110 - D03.633.100.079.150
└─

Fénoldopam

Fenoldopam D018818 - D03.633.100.079.300
└─

Galantamine

Galantamine D005702 - D03.633.100.079.525
└─

Ivabradine

Ivabradine D000077550 - D03.633.100.079.801
└─

1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D015647 - D03.633.100.079.838
└─

Tolvaptan

Tolvaptan D000077602 - D03.633.100.079.875
└─└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Bernhard Wünsch

9 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
Publications dans "Benzazépines" : Voir toutes les publications (9)

Dirk Schepmann

7 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" : Voir toutes les publications (7)

Simon M Ametamey

5 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.
Publications dans "Benzazépines" :

Nadine Ritter

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
  • Chembion, University of Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
Publications dans "Benzazépines" :

Guiscard Seebohm

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Alexander Markus

3 publications dans cette catégorie

Affiliations :
  • Institut für Pharmazeutische und Medizinische Chemie der Universität Münster, Münster, Germany.
Publications dans "Benzazépines" :

Paul Disse

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Julian A Schreiber

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nathalie Strutz-Seebohm

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nengneng Zhou

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Fangli Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Lei Wang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Xiang Gao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Xiaowei Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Man Zhang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Álvaro Velasco-Rubio

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Jesús A Varela

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Carlos Saá

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Yoshikazu Arai

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: arai.yoshikazu.mh@daiichisankyo.co.jp.
Publications dans "Benzazépines" :

Yohei Kiyotsuka

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Publications dans "Benzazépines" :

Sources (10000 au total)

Cannabinoids in movement disorders.

09 2022
DOI: 10.1016/j.parkreldis.2022.08.014 PMID: 36038457

On the basis of both scientific progress and popular lore, there is growing optimism in the therapeutic potential of cannabis (marijuana) and cannabinoid-based chemicals for movement disorders. There ... In recognition of the high interest and controversial nature of this subject, the meeting committee of the International Parkinson and Movement Disorders Society arranged for a talk on cannabis at the... The endocannabinoid system is strongly tied to motor function and dysfunction, with basic research suggesting several promising therapeutic targets related to cannabinoids for movement disorders. Clin... Further research is greatly needed to better understand the actual clinical benefits and long-term side effects of medical cannabis products for movement disorders indications and populations....

Adolescent Aged Cannabinoid Receptor Agonists Cannabinoids Endocannabinoids +3 autres

Impaired Metacognition of Voluntary Movement in Functional Movement Disorder.

03 2023
DOI: 10.1002/mds.29303 PMID: 36606550

Motor symptoms in functional movement disorders (FMDs) are experienced as involuntary but share characteristics of voluntary action. Clinical and experimental evidence indicate alterations in monitori... The objective of this study was to test the prediction that FMDs are associated with a reduced ability to make accurate (metacognitive) judgments about self-performed movements.... We compared 24 patients with FMD (including functional gait disturbance, functional tremor, and functional tics) with 24 age- and sex-matched healthy control subjects in a novel visuomotor-metacogniti... Patients and control subjects showed comparable motor performance, response accuracy, and use of the confidence scale. However, visuomotor sensitivity in the trajectory judgment was reduced in patient... Patients with FMD exhibited deficits both when making visuomotor decisions about their own movements and in the metacognitive evaluation of these decisions. Reduced metacognitive insight into voluntar...

Humans Metacognition Tremor Conversion Disorder Judgment +2 autres

Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease.

01 08 2022
DOI: 10.1097/WCO.0000000000001075 PMID: 35787539

The purpose of this review is to outline the impact of the COVID-19 pandemic on movement disorder holistic care, particularly in the care of people with Parkinson disease (PWP).... As the pandemic unfolds, a flurry of literature was published regarding the impact of COVID-19 on people with Parkinson disease including the direct impact of infection, availability of ambulatory car... COVID-19 has impacted the care of PWP in numerous ways. Recognizing infection in PWP poses challenges. Specific long-term complications, including emerging reports of long COVID syndrome is a growing ...

COVID-19 Humans Movement Disorders Pandemics Parkinson Disease +3 autres

Current opinions and practices in post-stroke movement disorders: Survey of movement disorders society members.

15 Mar 2024
DOI: 10.1016/j.jns.2024.122925 PMID: 38340409

Post-stroke movement disorders (PSMD) encompass a wide array of presentations, which vary in mode of onset, phenomenology, response to treatment, and natural history. There are no evidence-based guide... To survey current opinions and practices on the diagnosis and treatment of PSMD.... A survey was developed by the PSMD Study Group, commissioned by the International Parkinson's and Movement Disorders Society (MDS). The survey, distributed to all members, yielded a total of 529 respo... Parkinsonism (68%), hemiballismus/hemichorea (61%), tremor (58%), and dystonia (54%) were by far the most commonly endorsed presentation of PSMD, although this varied by region. Basal ganglia stroke (... Regionally varying opinions and practices on PSMD highlight gaps in (and mistranslation of) epidemiologic and therapeutic knowledge. Multicenter registries and prospective community-based studies are ...

Humans Prospective Studies Movement Disorders Stroke Tremor +1 autres

Movement disorders in hereditary spastic paraplegias.

Nov 2023
DOI: 10.1055/s-0043-1777005 PMID: 38035585

Hereditary or familial spastic paraplegias (SPG) comprise a group of genetically and phenotypically heterogeneous diseases characterized by progressive degeneration of the corticospinal tracts. The co... To summarize the clinical descriptions of SPG that manifest with movement disorders or ataxias to assist the clinician in the task of diagnosing these diseases.... We conducted a narrative review of the literature, including case reports, case series, review articles and observational studies published in English until December 2022.... Juvenile or early-onset parkinsonism with variable levodopa-responsiveness have been reported, mainly in SPG7 and SPG11. Dystonia can be observed in patients with SPG7, SPG11, SPG22, SPG26, SPG35, SPG... Patients with SPG may present with different forms of movement disorders such as parkinsonism, dystonia, tremor, myoclonus and ataxia. The specific movement disorder in the clinical manifestation of a...

Humans Spastic Paraplegia, Hereditary Mutation Tremor Dystonia +4 autres

Peripherally-induced Movement Disorders: An Update.

2023
DOI: 10.5334/tohm.758 PMID: 37008994

Peripherally-induced movement disorders (PIMD) should be considered when involuntary or abnormal movements emerge shortly after an injury to a body part. A close topographic and temporal association b... A comprehensive PubMed search through a broad range of keywords and combinations was performed in February 2023 to identify relevant articles for this narrative review.... The spectrum of the phenomenology of PIMD is broad and it encompasses both hyperkinetic and hypokinetic movements. Hemifacial spasm is probably the most common PIMD. Others include dystonia, tremor, p... There is considerable heterogeneity among PIMD in terms of severity and nature of injury, natural course, association with pain, and response to treatment. As some patients may have co-existing functi...

Humans Tremor Movement Disorders Dystonic Disorders Tic Disorders +2 autres